Payment overview · 2025
General Payments
$163.84
7 reported records · 3 companies
Healthcare provider profile · identity verified
Ajmal Mohammad, N.P.
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Psychiatric/Mental Health · LAWNDALE, CA · NPI 1700017712
Verified facts
What the public records show
CMS Open Payments records show Ajmal Mohammad, N.P. received $163.84 in general payments during 2025 across 7 reported records.
Vanda Pharmaceuticals Inc. accounted for 70.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Invega Sustenna, Invega Trinza.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Invega Trinza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $114.65 | 70.0% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.52 | 18.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.67 | 12.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $163.84 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $114.65 | 5 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $19.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 98 | exact normalized | Medicare Part D |
| INVEGA TRINZA invega trinza |
2025 | Invega Trinza | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
98 | 25 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA TRINZA open payments reported associated product |
CMS Open Payments — General Payments 8191 supporting records · 2146 recipient NPIs · example record 1174223262 |
Invega Trinza · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Divalproex Sodium | Divalproex Sodium | 443 | 90 |
| Quetiapine Fumarate | Quetiapine Fumarate | 438 | 79 |
| Risperidone | Risperidone | 396 | 83 |
| Trazodone Hcl | Trazodone Hcl | 386 | 70 |
| Olanzapine | Olanzapine | 365 | 68 |
| Benztropine Mesylate | Benztropine Mesylate | 340 | 56 |
| Sertraline Hcl | Sertraline Hcl | 296 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 270 | 44 |
| Lorazepam | Lorazepam | 270 | 95 |
| Mirtazapine | Mirtazapine | 205 | 43 |
| Gabapentin | Gabapentin | 198 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 196 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 41 |
| Aripiprazole | Aripiprazole | 172 | 34 |
| Haloperidol | Haloperidol | 168 | 30 |
| Buspirone Hcl | Buspirone Hcl | 151 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 20 |
| Olanzapine Odt | Olanzapine | 113 | 20 |
| Divalproex Sodium Er | Divalproex Sodium | 111 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 22 |
| Lisinopril | Lisinopril | 101 | 14 |
| Invega Sustenna | Paliperidone Palmitate | 98 | 25 |
| Furosemide | Furosemide | 95 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 21 |
| Levetiracetam | Levetiracetam | 75 | 15 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 70 | 13 |
| Glipizide | Glipizide | 68 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 66 | suppressed |
| Temazepam | Temazepam | 66 | 25 |
| Clonazepam | Clonazepam | 65 | 19 |
| Fenofibrate | Fenofibrate | 65 | suppressed |
| Aripiprazole Odt | Aripiprazole | 64 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | suppressed |
| Metformin Hcl | Metformin Hcl | 62 | 20 |
| Risperidone Odt | Risperidone | 58 | suppressed |
| Losartan Potassium | Losartan Potassium | 56 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 55 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 55 | 11 |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 14 |
| Atenolol | Atenolol | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Valsartan | Valsartan | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 43 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | suppressed |
| Famotidine | Famotidine | 40 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 18 |
| Lurasidone Hcl | Lurasidone Hcl | 38 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 37 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Omeprazole | Omeprazole | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 16 |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Lactulose | Lactulose | 29 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 14 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Simvastatin | Simvastatin | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Clozapine | Clozapine | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 23 | 11 |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Invega Hafyera | Paliperidone Palmitate | 22 | 11 |
| Latanoprost | Latanoprost | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Levocarnitine | Levocarnitine | 11 | suppressed |
| Orgovyx | Relugolix | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Thiothixene | Thiothixene | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $163.84 · 7 records | Vanda Pharmaceuticals Inc. | COBENFY, FANAPT, INVEGA SUSTENNA, INVEGA TRINZA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Invega Sustenna play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error